Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 478Neoplasms, Plasma Cell 102Lymphoma 86Lymphoma, Non-Hodgkin 75Leukemia, Lymphocytic, Chronic, B-Cell 72Myelodysplastic Syndromes 71Recurrence 68Leukemia, Myeloid, Acute 68Leukemia 68Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Hodgkin Disease 66Lymphoma, Mantle-Cell 53Lymphoma, Large B-Cell, Diffuse 53Lymphoma, Follicular 45Myeloproliferative Disorders 43Neoplasms 41Lymphoma, B-Cell, Marginal Zone 41Burkitt Lymphoma 41Primary Myelofibrosis 38Lymphoma, Large-Cell, Immunoblastic 36Lymphoma, T-Cell, Cutaneous 31Leukemia, Myelomonocytic, Chronic 31Sezary Syndrome 29Mycosis Fungoides 29Leukemia, Myeloid, Chronic-Phase 29Leukemia, Myeloid, Accelerated Phase 29Congenital Abnormalities 29Leukemia, Hairy Cell 27Blast Crisis 27Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25

Interventions

belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Bone Marrow Neoplasms × Plasma cell × Clear all
NCT00431340 2015-07-08

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Valerio Therapeutics

Phase 2 Terminated
4 enrolled
Plasma cell

Multiple Myeloma, Bone Marrow Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡